MXPA04002006A - Analogos de prostagladina como abridor del canal de cloruro. - Google Patents

Analogos de prostagladina como abridor del canal de cloruro.

Info

Publication number
MXPA04002006A
MXPA04002006A MXPA04002006A MXPA04002006A MXPA04002006A MX PA04002006 A MXPA04002006 A MX PA04002006A MX PA04002006 A MXPA04002006 A MX PA04002006A MX PA04002006 A MXPA04002006 A MX PA04002006A MX PA04002006 A MXPA04002006 A MX PA04002006A
Authority
MX
Mexico
Prior art keywords
channel opener
chloride channel
prostaglandin analogs
chloride
prostaglandin compound
Prior art date
Application number
MXPA04002006A
Other languages
English (en)
Spanish (es)
Inventor
Ueno Ryuji
Original Assignee
Sucampo Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26980134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA04002006(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sucampo Ag filed Critical Sucampo Ag
Publication of MXPA04002006A publication Critical patent/MXPA04002006A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA04002006A 2001-08-31 2002-08-29 Analogos de prostagladina como abridor del canal de cloruro. MXPA04002006A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31591701P 2001-08-31 2001-08-31
US37210402P 2002-04-15 2002-04-15
PCT/JP2002/008705 WO2003030912A1 (en) 2001-08-31 2002-08-29 Prostaglandin analogs as chloride channel opener

Publications (1)

Publication Number Publication Date
MXPA04002006A true MXPA04002006A (es) 2004-06-07

Family

ID=26980134

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04002006A MXPA04002006A (es) 2001-08-31 2002-08-29 Analogos de prostagladina como abridor del canal de cloruro.

Country Status (11)

Country Link
US (2) US7064148B2 (enExample)
EP (1) EP1420794B1 (enExample)
JP (2) JP4786866B2 (enExample)
AR (1) AR036391A1 (enExample)
AU (1) AU2002330747B2 (enExample)
BR (1) BR0212233A (enExample)
CA (1) CA2458471C (enExample)
MX (1) MXPA04002006A (enExample)
NZ (1) NZ531503A (enExample)
TW (1) TWI298256B (enExample)
WO (1) WO2003030912A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4597481B2 (ja) * 2001-05-18 2010-12-15 スキャンポ・アーゲー 下剤組成物
TWI331920B (en) 2001-11-14 2010-10-21 Sucampo Ag Unit dosage form for relieving or treating constipation in human patients
TWI263505B (en) * 2001-11-19 2006-10-11 Sucampo Ag Pharmaceutical composition comprising a C1C-2 channel opener
ES2379652T3 (es) * 2002-10-23 2012-04-30 Sucampo Ag Compuestos de prostaglandina para el tratamiento de obesidad
NZ541110A (en) * 2002-12-27 2008-11-28 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
WO2005002588A1 (en) * 2003-07-03 2005-01-13 Sucampo Ag Enteric coated composition comprising prostaglandin analogs as chloride channel opener
TWI348386B (en) * 2003-08-12 2011-09-11 R Tech Ueno Ltd Composition and method for promoting hair growth
TWI387454B (zh) 2004-09-02 2013-03-01 蘇坎波公司 治療胃腸道疾病之方法及組成物
JP5241484B2 (ja) * 2005-03-07 2013-07-17 ザ ユニヴァーシティー オヴ シカゴ 内皮細胞増殖及び内皮細胞遊走を減弱するためのオピオイドアンタゴニストの使用
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US20060281818A1 (en) * 2005-03-21 2006-12-14 Sucampo Ag, North Carolina State University Method for treating mucosal disorders
JP5711442B2 (ja) * 2005-04-12 2015-04-30 スキャンポ・アーゲーＳｕｃａｍｐｏ ＡＧ 胃腸障害の処置のためのプロスタグランジン化合物およびプロトンポンプ阻害剤の併用
CA2642744C (en) * 2006-02-28 2015-02-24 Sucampo Ag Method and composition for treating chronic obstructive pulmonary disease
US7868045B2 (en) * 2006-09-06 2011-01-11 Sucampo Ag Method for promoting gastrointestinal bicarbonate secretion
WO2008108322A2 (en) * 2007-02-27 2008-09-12 Sucampo Ag Composition and method for protecting mitochondria
US20090012165A1 (en) 2007-07-03 2009-01-08 Sucampo Ag Pharmaceutical combination of nsaid and prostaglandin compound
US20090030072A1 (en) 2007-07-03 2009-01-29 Sucampo Ag Pharmaceutical combination of opioid and prostaglandin compound
WO2009049159A1 (en) 2007-10-10 2009-04-16 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
CN101318948B (zh) * 2008-04-01 2011-04-27 上海天伟生物制药有限公司 鲁比前列酮晶体、其制备方法及用途
US20110034424A1 (en) * 2009-06-30 2011-02-10 Sucampo Ag Method for the long term nsaid use
ES2451790T3 (es) * 2009-08-07 2014-03-28 Scipharm Sàrl Composición para el tratamiento de la fibrosis quística
MX342548B (es) * 2009-09-18 2016-10-04 Merck Sharp & Dohme Corp * Uso del antagonista del receptor opiaceo para los trastornos del tracto gastrointestinal.
ME02598B (me) * 2011-02-07 2017-06-20 Scipharm Sarl Nova kompozicija za lečenje cistične fibroze
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
EP2717855A4 (en) 2011-06-07 2014-11-12 Parion Sciences Inc PROCESSING METHODS
US10724986B2 (en) 2012-11-29 2020-07-28 Indiana University Research & Technology Corporation Dielectric electrolyte measurement device
WO2014159679A1 (en) 2013-03-12 2014-10-02 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for using lubiprostone to absorb fluid from the subretinal space
US20150057351A1 (en) * 2013-08-22 2015-02-26 Sucampo Ag Method for treating neuropathic pain
EP3053575B1 (en) 2013-10-04 2020-09-02 Tohoku University Agent for preventing or ameliorating renal dysfunction
WO2018065826A1 (en) 2016-10-06 2018-04-12 Sucampo Ag Multilayer beads for pharmaceutical use
US11376287B2 (en) 2016-10-20 2022-07-05 Biofermin Pharmaceutical Co., Ltd. Agent acting on transcellular ion transporter in intestinal tract, agent for activating chloride channel, agent for preventing or treating renal disease, or agent for promoting defecation
US10457623B1 (en) * 2018-07-13 2019-10-29 Chirogate International Inc. Process for the preparation of Lubiprostone and intermediates thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE43462B1 (en) * 1975-06-23 1981-03-11 Pfizer Substituted tetranorprostaglandins
US4091207A (en) * 1976-04-22 1978-05-23 Pfizer Inc. Prostaglandin intermediate including oxathio heterocyclic ring
IT1098350B (it) * 1977-07-28 1985-09-07 Upjohn Co Derivati prostaglandinici
JPS6033429B2 (ja) * 1980-04-28 1985-08-02 小野薬品工業株式会社 プロスタグランジン類似化合物
US5166174A (en) 1987-01-28 1992-11-24 K.K. Ueno Seiyaku Oyo Kenkyujo Prostaglandins E and anti-ulcers containing same
CA1322749C (en) 1987-01-28 1993-10-05 Ryuzo Ueno Prostaglandins of the d series, and tranquilizers and soporifics containing the same
US5221763A (en) 1987-04-30 1993-06-22 R-Tech Ueno, Ltd. Prostaglandins of the F series
JPH0681728B2 (ja) * 1987-10-02 1994-10-19 株式会社上野製薬応用研究所 下 剤
ES2051862T3 (es) 1987-10-02 1994-07-01 Ueno Seiyaku Oyo Kenkyujo Kk Un metodo para producir un medicamento que tiene un efecto catartico.
JP2579193B2 (ja) 1988-07-19 1997-02-05 小野薬品工業株式会社 １６，１６−ジフルオロ−１５−オキソ−１５−デオキシｐｇｅ誘導体
JPH0791192B2 (ja) * 1989-11-22 1995-10-04 株式会社上野製薬応用研究所 ガス交換機能不全処置剤
CA2030344C (en) 1989-11-22 2000-04-18 Ryuji Ueno Treatment of pulmonary dysfunction with 15-keto-prostaglandin compounds
TW224942B (enExample) 1990-04-04 1994-06-11 Adka Ueno Kk
EP0455448B1 (en) 1990-05-01 1998-12-09 R-Tech Ueno Ltd. Treatment of pancreatic disease with 15-keto-prostaglandin E compounds
CA2150287C (en) * 1994-06-03 2004-08-10 Ryuji Ueno Agent for treating hepato-biliary diseases
US6015828A (en) 1996-05-31 2000-01-18 Cuppoletti; John Chemical modification of chloride channels as a treatment for cystic fibrosis and other diseases
WO1997047595A1 (en) 1996-06-10 1997-12-18 R-Tech Ueno, Ltd. Endothelin antagonist
NZ336362A (en) * 1997-10-13 2001-01-26 R Tech Ueno Ltd Use of a 15-keto-prostaglandin compound as a portal hypertension inhibitor
JP4319256B2 (ja) * 1997-11-28 2009-08-26 スキャンポ・アーゲー エンドセリン拮抗剤
JP4354644B2 (ja) * 1998-05-25 2009-10-28 大正製薬株式会社 プロスタグランジン誘導体
JP2003527430A (ja) 2000-03-24 2003-09-16 スカンポ・アクチェンゲゼルシャフト １５−ケトプロスタグランジンまたはその誘導体を含むアポトーシス抑制剤
MXPA02009915A (es) 2000-04-06 2003-03-27 Sucampo Ag Composicion promotora de secrecion de bilis.
TWI302100B (en) 2001-05-02 2008-10-21 Sucampo Ag Composition for treating drug-induced constipation
FR2829293B1 (fr) * 2001-08-31 2003-11-14 Centre Nat Rech Scient Memoire moleculaire et son procede de fabrication

Also Published As

Publication number Publication date
WO2003030912A1 (en) 2003-04-17
US7064148B2 (en) 2006-06-20
BR0212233A (pt) 2004-10-05
US7253295B2 (en) 2007-08-07
JP4786866B2 (ja) 2011-10-05
AR036391A1 (es) 2004-09-08
TWI298256B (en) 2008-07-01
CA2458471A1 (en) 2003-04-17
NZ531503A (en) 2006-01-27
EP1420794A1 (en) 2004-05-26
EP1420794B1 (en) 2017-12-27
CA2458471C (en) 2012-07-31
JP2011102313A (ja) 2011-05-26
AU2002330747B2 (en) 2007-07-19
JP2005504836A (ja) 2005-02-17
US20030130352A1 (en) 2003-07-10
US20060122411A1 (en) 2006-06-08
JP5568021B2 (ja) 2014-08-06

Similar Documents

Publication Publication Date Title
MXPA04002006A (es) Analogos de prostagladina como abridor del canal de cloruro.
IN2012DN00606A (enExample)
TW200626559A (en) Anilino-pyrimidine analogs
DE60309836D1 (de) Kristalline zeolithische aluminosilikat-zusammensetzung: uzm-9
PT1485359E (pt) Bloqueadores dos canais de sódio
MXPA03007450A (es) Metodos para producir dioxido de titanio practicamente libre de anatasa, con adicion de haluro de silicio.
EP1599096A4 (en) HETEROSUBSTITUTED SODIUM CHANNEL BLOCKERS
AU6337999A (en) Core-extended perylene bisimides
MXPA04000210A (es) Conjugados quelantes mejorados.
ATE292133T1 (de) Kaliumkanäleöffner
MXPA05013751A (es) Procedimiento e intermediarios para la preparacion de 3-(amino)-3-ciclobutilmetil-2-hidroxi-propionamida o sus sales.
MXPA02012944A (es) Analogos de acido graso para el tratamiento de cancer.
HRP20080057T3 (en) 9,10-alpha,alpha-oh-taxane analogs and methods for production thereof
ATE373642T1 (de) Kalium kanalaktivatoren
MXPA04001248A (es) Reduccion del crecimiento del vello.
GB2342352B (en) Pure cis-tramadol hydrochloride production
MXPA04005788A (es) Proceso para preparacion de derivados de [1,4,5]-oxadiazepina.
WO2002062762A3 (en) Potassium channel openers
ATE301190T1 (de) Protonen-abhängiges na+kanal hemmendes polypeptid
MXPA04002058A (es) Prueba.
IL156640A0 (en) A process for preparing arylethanoldiamine derivatives
TR200402199T4 (tr) Potasyum kanal açıcı olarak trisiklik dihidropiyrazolon ve trisiklik dihidroizoksazolon bileşikleri.
NO20100775L (no) Fremgangsmate for okning av utbyttet av et inerferon alfa-preparat
MXPA04000712A (es) METODOS PARA PROMOCION DE CRECIMIENTO DE CABELLO QUE COMPRENDEN APLICACION TOPICA DE ANaLOGOS DE PROSTAGLANDINA.
CA2514254A1 (en) Improved method for hydrocarbon isomerization

Legal Events

Date Code Title Description
FG Grant or registration